Galen in play
Executive Summary
Merger talks between women's health specialty company Galen and unidentified suitor (reportedly Barr) terminated July 21. Galen has recently expanded its product line via acquisition of Pfizer's women's health brands, Lilly's pre-menstrual dysphoric disorder agent Sarafem and the approval of Femring (1"The Pink Sheet" March 31, 2003, p. 29)...